Title |
-
Clinical Influence of Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors for Cardiovascular and Renal Points of View
|
Creator |
|
Rights |
-
© 2020 Bando H. This is an open-access article distributed under the Creative Commons Attribution License(https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
|
Subject |
-
Other
Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors
-
Other
Canagliflozin Cardio-Vascular Assessment Study (CANVAS)
-
Other
Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE)
-
Other
Dapagliflozin Effect on CardiovascuLAR Events (DECLARE) -TIMI 58
-
Other
The Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients-Removing Excess Glucose (EMPA-REG OUTCOME) Study
|
Description |
-
Other
Diabetes has been a major medical and health problem worldwide. Adequate glycemic control has shown a clinically beneficial effect for long-term prognosis, with recent anti-diabetic agents. There are some mega studies concerning Sodium-glucose cotransporter 2 (SGLT2) inhibitors. They are i) Canagliflozin cardioVascular Assessment Study (CANVAS), ii) Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE), iii) Dapagliflozin Effect on CardiovascuLAR Events (DECLARE) -TIMI 58, iv) Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients-Removing Excess Glucose (EMPA-REG OUTCOME) study. Current topics of SGLT2 inhibitors for cardiovascular and renal points of view were described.
|
Publisher |
Asploro
|
Date |
|
Language |
|
Resource Type |
journal article |
Version Type |
VoR |
Identifier |
URI
http://repo.lib.tokushima-u.ac.jp/114800
|
Relation |
-
isIdenticalTo
DOI
https://doi.org/10.36502/2020/droa.6156
|
Journal |
-
Diabetes Research : Open Access
-
Volume Number2
Issue NumberS1
Page Start9
Page End13
|
File |
|
Oaidate |
2023-06-26 |